drugset / Trial / NCT00856687

A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

NCT00856687

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

PF-03893787, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Timeline

Start
2009-04
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ADRIFORANT Small molecule Oral
Comparator Montelukast Other / unclassified Oral

Indications